Cargando…

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story

Detalles Bibliográficos
Autores principales:	Gebbia, Vittorio, Valerio, Maria Rosaria, Martorana, Federica, Sanò, Maria Vita, Vigneri, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Becaris Publishing Ltd 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402907/ https://www.ncbi.nlm.nih.gov/pubmed/37114420 http://dx.doi.org/10.57264/cer-2022-0212

Ejemplares similares

Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report
por: Gebbia, Vittorio, et al.
Publicado: (2021)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments
por: Nawa, Hideki, et al.
Publicado: (2021)

Development of a SPE-LC-MS Method for the Quantitation of Palbociclib and Abemaciclib in Human Plasma
por: Calucică, Daniela Maria, et al.
Publicado: (2022)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
por: Law, Ernest H, et al.
Publicado: (2023)

Abemaciclib in Patients with End-Stage Renal Disease and Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Report of 2 Cases
por: Gebbia, Vittorio
Publicado: (2022)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
por: Mlinarić, Zvonimir, et al.
Publicado: (2022)

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
por: Valerio, Maria Rosaria, et al.
Publicado: (2021)

Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review
por: Wender, Isabella O., et al.
Publicado: (2020)

Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase
por: Pandey, Kamal, et al.
Publicado: (2022)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Letter to the editor: Are the doors opened to a genetic-based algorithm for personalized resistance training?
por: Monnerat-Cahli, G, et al.
Publicado: (2016)

Letter to the editor: Cervical spondylotic myelopathy treated with laminectomy versus open-door laminoplasty
por: Ansari, Ahmed
Publicado: (2020)

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
por: Cejuela, Mónica, et al.
Publicado: (2023)

Abemaciclib for breast cancer
Publicado: (2020)

WhatsApp Messenger use in oncology: a narrative review on pros and contras of a flexible and practical, non-specific communication tool
por: Gebbia, Vittorio, et al.
Publicado: (2021)

The NuRD Complex in Neurodevelopment and Disease: A Case of Sliding Doors
por: Boulasiki, Paraskevi, et al.
Publicado: (2023)

Letter to the Editor: Appropriate Statistical Analysis and Research Reporting
por: Misra, Durga Prasanna, et al.
Publicado: (2017)

Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients’ Queries, Needs, Fears, and Actions Taken
por: Gebbia, Vittorio, et al.
Publicado: (2020)

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
por: Martínez-Chávez, Alejandra, et al.
Publicado: (2019)

Decreased sensitivity of cyclin-dependent kinase 4/6 inhibitors, palbociclib and abemaciclib to canine lymphoma cells with high p16 protein expression and low retinoblastoma protein phosphorylation
por: MAYLINA, Leni, et al.
Publicado: (2022)

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review
por: Mao, Yan, et al.
Publicado: (2023)

Editor's Letter-Box
por: Poole, Maria
Publicado: (1900)

Reply to letter to the editor
por: Vailas, Michail, et al.
Publicado: (2021)

Letter to the Editor [Letter]
por: Félix, Sylvie
Publicado: (2021)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
por: Turković, Lu, et al.
Publicado: (2022)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

Letter to the Editor
Publicado: (1997)

Letter to the Editor
por: Wölner-Hanssen, Pål
Publicado: (1996)

Letter to The Editor
por: Goldring, J. R.
Publicado: (1989)

Letters to the Editor
Publicado: (1998)

Letter to the Editor
por: Pouwer, Frans
Publicado: (2008)

Letters to the Editor
por: Levine, Elliott M.
Publicado: (2001)

Letter to the editor
por: Kanna, Balavenkatesh, et al.
Publicado: (2005)

Letters to the Editor
por: McKenna, Michael J.
Publicado: (1979)

Letter to the editor
por: Rosival, Viktor
Publicado: (2005)

Letter to the Editor
por: Clair, R. E. Wright-St.
Publicado: (1973)

Cannot write session to /tmp/vufind_sessions/sess_iguv4pak57epiflovrsu81idrp